



# 13<sup>TH</sup> NEURO-ONCOLOGY BRAIN TUMOR SYMPOSIUM

CME/CNE-accredited and patient & caregiver program



**FRIDAY, JANUARY 30, 2026**

## AGENDA

**7:00 am IN-PERSON: Check In, Breakfast, Visit Exhibits and Experts**

### ASK THE EXPERTS

Patient Advocacy	Dellan Elliot Mydland
Reiki	Alexandra Kurowski DiFilippo
Social Work – Coping with Emotions	Tiffany Raroha, MSW, LCSW

**7:30 am VIRTUAL: Log in to Virtual Conference**

**7:40 am Educational Symposium Begins – Welcome Address & Introduction**  
Nduka M. Amankulor, MD | Activity Director | Neurosurgery  
Steven Brem, MD | Activity Director | Neurosurgery  
Daniel Yoshor, MD | Neurosurgery  
Robert H. Vonderheide, MD, DPhil | Abramson Cancer Center

### SCIENTIFIC SESSION I: ADVANCES IN MOLECULAR PROFILING AND NEUROIMAGING

**MODERATOR:** Steven Brem, MD | Activity Director | Neurosurgery

**8:00 am KEYNOTE ADDRESS: *From Methylation to Management: Precision Decisions for Brain Metastases and Meningioma***  
Gelareh Zadeh, MD, PhD | Neurosurgery | Mayo Clinic

**8:30 am Dynamic Diagnostics in Gliomas: The Role of Molecular Profiling and AI/ML**  
MacLean Nasrallah, MD, PhD | Pathology & Laboratory Medicine

**8:40 am Next Generation Sequencing (NGS) in Glioblastoma: *What's Actionable in the Clinic?***  
Jennifer J.D. Morrisette, PhD | Pathology & Laboratory Medicine

**8:50 am *From Pixels to Prognosis: RANO 2.0 and Advances in Neuro(oncologic)imaging for Clinical Decision Making***  
Suyash Mohan, MD, PDCC | Activity Co-Director | Radiology

# 13<sup>TH</sup> NEURO-ONCOLOGY BRAIN TUMOR SYMPOSIUM

CME/CNE-accredited and patient & caregiver program



**9:05 am** **Amino Acid PET in Neuro Oncology: *Advantages and Challenges***  
[Ali Nabavizadeh, MD](#) | Radiology

**9:15 am** **Q&A Panel Discussion**  
**MODERATOR:** [Steven Brem, MD](#) | Activity Director | Neurosurgery  
**PANEL:**  
[Suyash Mohan, MD, PDCC](#) | Activity Co-Director | Radiology  
[Jennifer J.D. Morrissette, PhD](#) | Pathology & Laboratory Medicine  
[Ali Nabavizadeh, MD](#) | Radiology  
[MacLean Nasrallah, MD, PhD](#) | Pathology & Laboratory Medicine  
[Gelareh Zadeh, MD, PhD](#) | Neurosurgery | Mayo Clinic

**9:35 am** ***Stories of Patient Survivors: Navigating the Health Care System, Finding Information, Clinical Trials, Innovation, & Hope***  
[Kaileen M. Bevenour, PA-C](#) | Neuro-Oncology  
[Elizabeth Heisler, PA-C](#) | Neuro-Oncology  
[Arbena Merolli Trettin, MSW](#) | Neurosurgery  
[Meghan O'Neill, CRNP](#) | Medical Oncology

**10:05 am** **Special Town Hall Meeting with Drs. Steven Brem, Nduka Amankulor and Arati Desai for Patients, Caregivers, & Family Members**  
[Nduka M. Amankulor, MD](#) | Activity Director | Neurosurgery  
[Steven Brem, MD](#) | Activity Director | Neurosurgery  
[Arati Desai, MD](#) | Activity Co-Director | Neuro-Oncology

**10:25 am** **Break / Visit Exhibits / Chat with Experts**

## SCIENTIFIC SESSION II: IMMUNOTHERAPY IN NEURO-ONCOLOGY


**MODERATOR:** [Nduka M. Amankulor, MD](#) | Activity Director | Neurosurgery

**10:40 am** **Recent and Ongoing Immunotherapy Clinical Trials for GBM**  
[Stephen J. Bagley, MD, MSCE](#) | Activity Co-Director | Hematology Oncology

**10:55 am** **History and Current State of the Penn CAR-T Cell Program for GBM**  
[Zev Binder, MD, PhD](#) | Neurosurgery

# 13<sup>TH</sup> NEURO-ONCOLOGY BRAIN TUMOR SYMPOSIUM

CME/CNE-accredited and patient & caregiver program



**11:10 am** ***Biomarkers in Immuno-Oncology: Road to Personalized Immunotherapy***  
[Christina Jackson, MD](#) | Neurosurgery

**11:25 am** ***From Data to Decisions: Genomics-Guided Surgery and Immunotherapy for Gliomas***  
[Nduka M. Amankulor, MD](#) | Activity Director | Neurosurgery

**11:40 am** **Q&A Panel Discussion**  
**MODERATOR:** [Nduka M. Amankulor, MD](#) | Activity Director | Neurosurgery  
**PANEL:**  
[Linda J. Bagley, MD](#) | Radiology and Neurosurgery  
[Stephen J. Bagley, MD, MSCE](#) | Activity Co-Director | Hematology Oncology  
[Zev Binder, MD, PhD](#) | Neurosurgery  
[Eric B. Hintz, MD](#) | Lancaster General Health  
[Christina Jackson, MD](#) | Neurosurgery

**12:00 pm** **Lunch / Visit Exhibits / Chat with Experts**

## SCIENTIFIC SESSION III: PROGRESS IN THE TREATMENT OF MALIGNANT GLIOMAS

**MODERATOR:** [Suyash Mohan, MD, PDCC](#) | Activity Co-Director | Radiology

**1:00 pm** **KEYNOTE ADDRESS: *INDIGO Lessons: Who and When to Treat with Vorasidenib***  
[Timothy F. Cloughesy, MD](#) | Neuro-Oncology | UCLA

**1:30 pm** ***Epigenetic Mechanisms in Glioma: Translating DMG Biology to Novel Treatments***  
[Richard E. Phillips, MD, PhD](#) | Neuro-Oncology

**1:45 pm** ***Medical (and Symptom) Management of Patients with Brain Tumors: A Practical Toolkit***  
[Amy A. Pruitt, MD](#) | Neurology

**2:00 pm** **Q&A Panel Discussion**  
**MODERATOR:** [Juan Pablo Ospina Botero, MD](#) | Neuro-Oncology  
**PANEL:**  
[Timothy F. Cloughesy, MD](#) | Neuro-Oncology | UCLA  
[Richard E. Phillips, MD, PhD](#) | Neuro-Oncology  
[Amy A. Pruitt, MD](#) | Neurology

# 13<sup>TH</sup> NEURO-ONCOLOGY BRAIN TUMOR SYMPOSIUM

CME/CNE-accredited and patient & caregiver program



2:15 pm      Break / Visit Exhibits / Chat with Experts

## SCIENTIFIC SESSION IV: ADVANCES IN PRECISION NEURO-ONCOLOGY

**MODERATOR:** [Goldie A. Kurtz, MD](#) | Activity Co-Director | Radiation Oncology

2:35 pm      **Translating Technology to Clinical Trials & Survivorship**  
[Steven Brem, MD](#) | Activity Director | Neurosurgery

2:50 pm      ***Protons, Photons, and FLASH: Advances in Radiation Therapy That Matter for Patients***  
[Emily Lebow, MD](#) | Radiation Oncology

3:05 pm      **Updates in the Targeted and Immunological Treatment of Brain Metastases**  
[Tara C. Mitchell, MD](#) | Hematology Oncology

3:20 pm      **Updates in Liquid Biopsy for Brain Tumors**  
[Stephen J. Bagley, MD, MSCE](#) | Activity Co-Director | Hematology Oncology

3:35 pm      **Q&A Panel Discussion**

**MODERATOR:** [Goldie A. Kurtz, MD](#) | Activity Co-Director | Radiation Oncology

**PANEL:**

[Stephen J. Bagley, MD, MSCE](#) | Activity Co-Director | Hematology Oncology

[Emily Lebow, MD](#) | Radiation Oncology

[Steven Brem, MD](#) | Activity Director | Neurosurgery


[Tara C. Mitchell, MD](#) | Medical Oncology

4:10 pm      **Concluding Remarks**

4:20 pm      **Conference Adjourns**

# 13<sup>TH</sup> NEURO-ONCOLOGY BRAIN TUMOR SYMPOSIUM

CME/CNE-accredited and patient & caregiver program



## Post Conference Details

After the conference has concluded, all attendees will receive an email from Penn CME with instructions on how to complete the post-test, evaluation, claim credit and obtain a certificate. Look for the email the week after the conference.

If you missed the Pre-Test, you will still be eligible to obtain your certificate after you complete the Post-Test and Evaluation. A [Certificate of Participation](#) is available to attendees who are not physicians or nurses.

## Meeting Videos

Website: [PennMedicine.org/Abramson/Brain2026](http://PennMedicine.org/Abramson/Brain2026)

*\*Recordings from the meeting will be available Thursday, February 5, 2026, through February 2027*

### Preliminary Data References

Please note that some of the studies reported in this CE activity may have been published as abstracts only and/or presented at a conference. In these cases, the references provided in individual presentations reflect that and will be easy for you to recognize. These data and conclusions are included because expert faculty found them to be potentially important scientific contributions but should be considered preliminary until published in a peer-reviewed journal.

## Overview

The purpose of this educational activity is to provide a review of new treatment options in neuro-oncology, including surgical techniques, and intraoperative imaging, along with, radiation and systemic therapies that have improved patient outcomes. Sessions will feature the latest advances in state-of-the-art care for practicing clinicians treating patients with brain tumors. Cutting-edge topics in precision medicine, including genetic, translational, and clinical research will also be featured. Activity format will provide significant opportunity for interaction with expert faculty and other attendees with the aim of implementing new standards of patient care. Participants will leave with up-to-date, practical information which will have immediate clinical application, as well as technical and scientific background on the current state, and where the latest scientific advances may take the field.

# 13<sup>TH</sup> NEURO-ONCOLOGY BRAIN TUMOR SYMPOSIUM

CME/CNE-accredited and patient & caregiver program



## Learning Objectives

Upon completion of this course, participants should be able to:


- Integrate next-generation sequencing (NGS) and methylation profiling data to inform personalized diagnostic, prognostic, and management decisions for patients with brain tumors, particularly gliomas and meningiomas.
- Utilize advancements in neuroimaging, including radiogenomics and amino acid PET, to enhance diagnostic accuracy and guide clinical decision-making in the neuro-oncology clinic
- Appraise the latest clinical trial data on novel immunotherapeutic approaches, including CAR-T cell therapy, and identify appropriate patient candidates and management considerations for these emerging treatments.
- Incorporate the key findings from the INDIGO trial to determine the optimal timing and patient selection for Vorasidenib in the treatment of IDH-mutant low-grade gliomas.
- Develop a practical toolkit for the comprehensive medical and symptom management of patients with brain tumors, focusing on improving their quality of life and functional status.
- Evaluate the clinical utility of new technologies, such as liquid biopsy and intraoperative molecular imaging, for improving the diagnosis, monitoring, and surgical precision of brain tumor treatment.
- Summarize the latest advancements in radiation therapy (protons, photons, FLASH) and targeted/immunological treatments for brain metastases to optimize patient care and improve outcomes.

## For Patients, Caregivers, and Advocates:

- Gain a clear understanding of cutting-edge treatment innovations and identify the essential resources needed to navigate the healthcare system effectively for shared decision-making.
- Learn how to translate complex research into practical needs, access reliable support networks, and apply actionable strategies for improving quality of life throughout the brain tumor journey.

# 13<sup>TH</sup> NEURO-ONCOLOGY BRAIN TUMOR SYMPOSIUM

CME/CNE-accredited and patient & caregiver program



## Accreditation



In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

## Designation of Credit

**PHYSICIANS:** Penn Medicine designates this live activity for a maximum of 7.0 AMA PRA *Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**NURSES:** The program awards 7.0 NCPD hours.

## Activity Directors

### **Nduka M. Amankulor, MD**

Presidential Associate Professor in Neurosurgery Chief, Neurosurgical Oncology  
Director, Penn Brain Tumor Center  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

### **Steven Brem, MD**

Professor of Neurosurgery  
Director, Medical Student Education, Neurosurgery  
Medical Director, Center for Precision Surgery, Abramson Cancer Center  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

# 13<sup>TH</sup> NEURO-ONCOLOGY BRAIN TUMOR SYMPOSIUM

CME/CNE-accredited and patient & caregiver program



## Activity Co-Directors

### **Stephen J. Bagley, MD, MSCE**

Assistant Professor of Medicine (Hematology-Oncology)  
Section Chief, Neuro-Oncology  
Clinical Director, Penn Brain Tumor Center  
Perelman School of Medicine at the University of Pennsylvania/ Penn Medicine  
Philadelphia, PA, USA

### **Arati Desai, MD**

Associate Professor of Medicine (Hematology Oncology)  
Co-Director, Penn Brain Tumor Center  
Perelman School of Medicine at the University of Pennsylvania/ Penn Medicine  
Philadelphia, PA, USA

### **Elizabeth Heisler, PA-C\***

Physician Assistant, Neuro-Oncology  
Penn Medicine  
Philadelphia, PA, USA

### **Goldie Kurtz, MD**

Associate Professor of Radiation Oncology  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA


### **Suyash Mohan, MD, PDCC**

Professor of Radiology & Neurosurgery Director, Neuroradiology Clinical Research Division  
Department of Radiology, Division of Neuroradiology  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

*\*Patient Coordinator*

# 13<sup>TH</sup> NEURO-ONCOLOGY BRAIN TUMOR SYMPOSIUM

CME/CNE-accredited and patient & caregiver program



## Guests & Penn Faculty

### **Linda J. Bagley, MD**

Associate Professor of Radiology and Neurosurgery  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

### **Kaileen M. Bevenour, PA-C**

Physician Assistant (Hematology, Medical Oncology)  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

### **Zev Binder, MD, PhD**

Research Assistant Professor, Department of Neurosurgery  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

### **Timothy F. Cloughesy, MD**


Distinguished Professor and Co-Director of UCLA Brain Tumor Center  
Director, UCLA Neuro-Oncology Program  
Director, Henry F. Singleton Brain Cancer Research Program  
David Geffen School of Medicine at The University of California, Los Angeles  
Los Angeles, CA USA

### **Eric B. Hintz, MD**

Neurosurgery  
Lancaster General Health / Penn Medicine  
Lancaster, PA, USA

# 13<sup>TH</sup> NEURO-ONCOLOGY BRAIN TUMOR SYMPOSIUM

CME/CNE-accredited and patient & caregiver program



## **Christina Jackson, MD**

Assistant Professor of Neurosurgery

Assistant Professor of Neurosurgery in Otorhinolaryngology: Head and Neck Surgery

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

## **Emily Lebow, MD**

Assistant Professor of Radiation Oncology

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

## **Tara C. Mitchell, MD**

Associate Professor of Medicine (Hematology Oncology)

Section Chief, Melanoma and Sarcoma, Hematology-Oncology

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

## **Jennifer J.D. Morrissette, PhD**

Associate Professor of Clinical Pathology and Laboratory Medicine

Clinical Director, Center for Personalized Diagnostics

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

## **Ali Nabavizadeh, MD**


Associate Professor of Radiology

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

Philadelphia, PA, USA

# 13<sup>TH</sup> NEURO-ONCOLOGY BRAIN TUMOR SYMPOSIUM

CME/CNE-accredited and patient & caregiver program



## **MacLean Nasrallah, MD, PhD**

Assistant Professor of Clinical Pathology and Laboratory Medicine  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

## **Juan Pablo Ospina Botero, MD**

Associate Professor of Neuro-Oncology  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

## **Meghan O'Neill, CRNP**

Nurse Practitioner (Hematology, Medical Oncology)  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

## **Amy A. Pruitt, MD**

William N. Kelley Professor of Neurology  
Vice Chair of Education  
Advisory Dean  
Division Chief, General Neurology  
Perelman School of Medicine at the University of Pennsylvania / Penn Medicine  
Philadelphia, PA, USA

## **Richard E. Phillips, MD PhD**


Presidential Assistant Professor of Neurology  
Chief, Division of Neuro-Oncology, Department of Neurology  
Perelman School of Medicine, University of Pennsylvania  
Neuro-Oncology Fellowship Director, Department of Neurology, University of Pennsylvania

## **Arbena Merolli Trettin, MSW**

Social Worker  
Manager of Patient Affairs  
Penn Medicine  
Philadelphia, PA, USA

# 13<sup>TH</sup> NEURO-ONCOLOGY BRAIN TUMOR SYMPOSIUM

CME/CNE-accredited and patient & caregiver program



## **Robert H. Vonderheide, MD, DPhil**

Director, Abramson Cancer Center

John H. Glick Abramson Cancer Center's Director Professor

Vice Dean for Cancer Programs, Perelman School of Medicine

Vice President for Cancer Programs, UPHS

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

## **Daniel Yoshor, MD**

Charles Harrison Frazier Professor of Neurosurgery

Chair, Department of Neurosurgery

Vice President, Clinical Integration and Innovation

Perelman School of Medicine at the University of Pennsylvania / Penn Medicine

## **Gelareh Zadeh, MD, PhD**


Consultant and chair of the Department of Neurologic Surgery

Mayo Clinic

Rochester, MN, USA

# 13<sup>TH</sup> NEURO-ONCOLOGY BRAIN TUMOR SYMPOSIUM

CME/CNE-accredited and patient & caregiver program



## Disclosure of Financial Relationships

The staff in the Office of Continuing Medical and Inter-Professional Education at Penn Medicine and the listed Planning Committee members (\*) for this activity have disclosed that they have no financial relationships with any ineligible companies related to the content of this educational activity. In accordance with ACCME Standards, all individuals in control of content are required to disclose any financial relationships with ineligible companies that occurred within the past 24 months, regardless of whether the relationship is ongoing or has ended.

The following faculty and Planning Committee Members (\*) have disclosed that they have no financial relationships with any ineligible companies related to the content of this educational activity.

Nduka M. Amankulor, MD*	Eric B. Hintz, MD	Amy Pruitt, MD
Linda J. Bagley, MD	Goldie Kurtz, MD*	Hyacen Putmon
Kaileen Bevenour, PA-C	Emily Lebow, MD	Arbena Merolli Trettin, MSW
Steven Brem, MD*	Barbara Lopez	Robert Vonderheide, MD
Juan Pablo Ospina Botero, MD	MacLean Nasrallah, MD	Daniel Yoshor, MD
Arati Desai, MD*	Meghan R. O'Neill, CRNP RN*	Gelareh Zadeh, PhD
Elizabeth Heisler, PA-C*	Richard Phillips, MD, PhD	

The following faculty and Planning Committee member(s)\* have disclosed all financial relationships with ineligible companies. All relevant financial relationships with ineligible companies are listed below. All relevant financial relationships have been mitigated.

### **Stephen Bagley, MD\***

Grant or research support-Incyte Corporation|Honoraria-Jazz (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Modifi Bio (Relationship has ended)|Grant or research support-Kite Pharma|Grant or research support-Eli Lilly (Relationship has ended)|Grant or research support-Novocure (Relationship has ended)|Grant or research support-Glaxo Smith Kline (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Servier|Honoraria-Servier (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Telix (Relationship has ended)|Consulting Fee-Nexus Neurotech (Relationship has ended)

# 13<sup>TH</sup> NEURO-ONCOLOGY BRAIN TUMOR SYMPOSIUM

CME/CNE-accredited and patient & caregiver program



## **Zev Binder, MD, PhD**

Independent Contractor (included contracted research)-Kite Pharma

## **Timothy F. Cloughesy, MD**

Consulting Fee-Thrid Rock (Relationship has ended)|Consulting Fee-Symbio (Relationship has ended)|Consulting Fee-MundiPharma (Relationship has ended)|Consulting Fee-Tango (Relationship has ended)|Consulting Fee-BlueRock (Relationship has ended)|Consulting Fee-Lista Therapeutics (Relationship has ended)|Consulting Fee-Stemline (Relationship has ended)|Consulting Fee-Novartis (Relationship has ended)|Consulting Fee-Roche (Relationship has ended)|Consulting Fee-Sonalasense (Relationship has ended)|Consulting Fee-Sagimet (Relationship has ended)|Consulting Fee-Servier|Consulting Fee-Jubilant (Relationship has ended)|Consulting Fee-ImmVira (Relationship has ended)|Consulting Fee-Gan & Lee (Relationship has ended)|Consulting Fee-BrainStorm (Relationship has ended)|Consulting Fee-Katmai|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Katmai|Royalties or Patent Beneficiary-Katmai|Stocks in any amount, excluding diversified mutual funds of a publicly traded company-Katmai|Stock options in any amount of a publicly traded or privately owned (non-publicly traded) company-Katmai|Consulting Fee-Sapience|Consulting Fee-Inovio (Relationship has ended)|Consulting Fee-DNAtrix (Relationship has ended)|Consulting Fee-Tyme (Relationship has ended)|Consulting Fee-SDP (Relationship has ended)|Consulting Fee-Kintara (Relationship has ended)|Consulting Fee-Bayer (Relationship has ended)|Consulting Fee-Boehringer Ingelheim (Relationship has ended)|Consulting Fee-VBL (Relationship has ended)|Consulting Fee-Amgen (Relationship has ended)|Consulting Fee-Kiyatec (Relationship has ended)|Consulting Fee-Novocure (Relationship has ended)|Consulting Fee-Imvax (Relationship has ended)|Consulting Fee-Exelixis (Relationship has ended)|Consulting Fee-Pathos (Relationship has ended)|Consulting Fee-Jazz Pharma (Relationship has ended)|Royalties or Patent Beneficiary-Jazz Pharma

## **Christina Jackson, MD**

Consulting Fee-Stryker

## **Tara C. Mitchell, MD**


Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck & Co|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Tempus|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb

# 13<sup>TH</sup> NEURO-ONCOLOGY BRAIN TUMOR SYMPOSIUM

CME/CNE-accredited and patient & caregiver program

**Suyash Mohan, MD, PDCC\***

Grant or research support-Novocure|Grant or research support-Galileo CDS



**Jennifer J.D. Morissette, PhD**

Advisor-AbbVie, Inc. (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds of a publicly traded company-ThermoFisher|Stocks or stock options, excluding diversified mutual funds of a publicly traded company-AbbVie, Inc.|Stocks or stock options, excluding diversified mutual funds of a publicly traded company-Johnson & Johnson|Stocks or stock options, excluding diversified mutual funds of a publicly traded company-Pfizer, Inc.

**Ali Nabavizadeh, MD**

Consulting Fee-Blue Earth Diagnostics (Relationship has ended)|Consulting Fee-Telix|Independent Contractor (included contracted research)-Telix

*\*Planning Committee*

# 13<sup>TH</sup> NEURO-ONCOLOGY BRAIN TUMOR SYMPOSIUM

CME/CNE-accredited and patient & caregiver program



## ACKNOWLEDGMENT OF COMMERCIAL SUPPORT

We gratefully acknowledge

**DayOne Biopharmaceuticals**

**Musella Foundation For Brain Tumor Research & Information**

**National Brain Tumor Society**

for providing an educational grant

---

## THANK YOU TO OUR EXHIBITORS

### Premier Level Exhibits

Servier

Stryker

Telix

### Gold Level Exhibit

DayOne Biopharmaceuticals

Integra Life Sciences

### Platinum Level Exhibits

Brainlab

Caris Life Sciences

GE Healthcare

GT Medical Technologies

Novocure

SpringWorks Therapeutics

### Non-Profits & Experts

End Brain Cancer Initiative (EBCI)

Head for the Cure

National Brain Tumor Society

Patient Advocacy

Reiki

Sails of Hope Chesapeake

Social Work